IMRX (Immuneering Corporation Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IMRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | Andrew Gengos | Chief Financial Officer | A | — | — |
| 2026-06-24 | Benjamin J. Zeskind | PRESIDENT AND CEO | Buy | — | — |
| 2026-06-16 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | Buy | — | — |
| 2026-06-11 | LAURIE KEATING | Director | A | — | — |
| 2026-06-11 | ROBERT J CARPENTER | Director | A | — | — |
| 2026-06-11 | DIANA HAUSMAN | Director | A | — | — |
| 2026-06-11 | Peter Feinberg | Director | A | — | — |
| 2026-06-11 | Thomas J. Schall | Director | A | — | — |
| 2026-03-17 | Leah R Neufeld | CHIEF PEOPLE OFFICER | A | — | — |
| 2026-02-05 | Leah R Neufeld | CHIEF PEOPLE OFFICER | A | — | — |
| 2026-02-05 | Mallory Morales | SVP Finance, CAO | A | — | — |
| 2026-02-05 | Igor Matushansky | Chief Medical Officer | A | — | — |
| 2026-02-05 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2026-02-05 | Harold Eugene Brakewood | Chief Business Officer | A | — | — |
| 2026-02-05 | Michael Bookman | CHIEF LEGAL OFFICER, SECRETARY | A | — | — |
| 2026-02-05 | Benjamin J. Zeskind | PRESIDENT AND CEO | A | — | — |
| 2026-01-21 | Harold Eugene Brakewood | Chief Business Officer | Buy | — | — |
| 2026-01-20 | Thomas J. Schall | Director | Buy | — | — |
| 2026-01-16 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | Buy | — | — |
| 2026-01-15 | Leah R Neufeld | CHIEF PEOPLE OFFICER | Buy | — | — |
| 2026-01-14 | Peter Feinberg | Director | Buy | — | — |
| 2026-01-02 | LAURIE KEATING | Director | A | — | — |
| 2026-01-02 | Peter Feinberg | Director | A | — | — |
| 2025-10-07 | Peter Feinberg | Director | Buy | — | — |
| 2025-10-02 | Leah R Neufeld | CHIEF PEOPLE OFFICER | Buy | — | — |
| 2025-10-02 | Mallory Morales | Chief Accounting Officer | Buy | — | — |
| 2025-10-02 | Michael Bookman | CHIEF LEGAL OFFICER, SECRETARY | Buy | — | — |
| 2025-10-01 | Peter Feinberg | Director | Buy | — | — |
| 2025-09-30 | Peter Feinberg | Director | Buy | — | — |
| 2025-09-17 | Leah R Neufeld | CHIEF PEOPLE OFFICER | A | — | — |
| 2025-09-17 | Mallory Morales | Chief Accounting Officer | A | — | — |
| 2025-09-17 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2025-07-07 | Leah R Neufeld | CHIEF PEOPLE OFFICER | Buy | — | — |
| 2025-07-07 | DIANA HAUSMAN | Director | Buy | — | — |
| 2025-07-03 | Benjamin J. Zeskind | PRESIDENT AND CEO | Buy | — | — |
| 2025-06-30 | Thomas J. Schall | Director | Buy | — | — |
| 2025-06-24 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | Buy | — | — |
| 2025-06-24 | Harold Eugene Brakewood | Chief Business Officer | Buy | — | — |
| 2025-06-23 | Peter Feinberg | Director | Buy | — | — |
| 2025-06-20 | Benjamin J. Zeskind | PRESIDENT AND CEO | Buy | — | — |
| 2025-06-18 | Thomas J. Schall | Director | Buy | — | — |
| 2025-06-16 | DIANA HAUSMAN | Director | A | — | — |
| 2025-06-16 | ROBERT J CARPENTER | Director | A | — | — |
| 2025-06-16 | LAURIE KEATING | Director | A | — | — |
| 2025-06-16 | ANN E BERMAN | Director | A | — | — |
| 2025-06-16 | Peter Feinberg | Director | A | — | — |
| 2025-06-16 | Thomas J. Schall | Director | A | — | — |
| 2025-03-24 | Igor Matushansky | Chief Medical Officer | A | — | — |
| 2025-02-07 | Harold Eugene Brakewood | Chief Business Officer | A | — | — |
| 2025-02-07 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,294,173 | — |
| — | PRESIDENT AND CEO | 3,210,179 | — |
| — | 10%+ Owner | 1,702,628 | — |
| — | Director | 823,839 | — |
| — | CHIEF SCIENTIFIC OFFICER | 382,531 | — |
| — | Director | 292,207 | — |
| — | Director | 74,530 | — |
| — | Director | 67,465 | — |
| — | CHIEF PEOPLE OFFICER | 29,598 | — |
| — | SVP Finance, CAO | 27,533 | — |
| — | Director | 14,000 | — |
| — | Chief Business Officer | 11,050 | — |
| — | CFO, TREASURER | 7,898 | — |
| — | CHIEF MEDICAL OFFICER | 7,563 | — |
| — | Director | 5,500 | — |
| — | CHIEF LEGAL OFFICER, SECRETARY | 4,870 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMRX quote page; the site-wide leaderboard is on the insider transactions hub.